Tecentriq (atezolizumab): Insurance Coverage and Denials
A plain-language guide to PD-L1 immune checkpoint inhibitor coverage, why insurers deny it, and where to get cancer-specific help.
Tecentriq is an immunotherapy known as a PD-L1 blocking antibody. It binds PD-L1 on tumor and immune cells, interrupting the signal that lets some cancers evade immune T cells and helping restore an anti-tumor immune response. The FDA has approved Tecentriq across several cancers, including certain non-small cell lung, small cell lung, hepatocellular, melanoma, and alveolar soft part sarcoma indications, often based on biomarkers such as PD-L1 expression or on the treatment setting.
Insurers commonly require prior authorization and frequently ask for PD-L1 testing results, confirmation of tumor type and stage, and proof that the requested use matches an approved indication. Denials and delays often involve combination-regimen questions or site-of-care infusion policies.
If your plan denies coverage, you generally have the right to an internal appeal and then an independent external review under federal rules such as 45 CFR 147.136. For dedicated cancer help, contact the PAN Foundation, Patient Advocate Foundation, Triage Cancer, CancerCare, or Genentech's Tecentriq copay and patient-assistance programs.
Where to get cancer-specific help
A note on scope. Apellica focuses on appeals for non-oncology insurance denials and does not handle cancer-related appeal cases. Cancer coverage involves complex, fast-moving clinical and financial questions, and patients are best served by organizations built specifically for oncology. If you are facing a cancer drug denial, please reach out to the specialized groups listed on this page, including the PAN Foundation, the Patient Advocate Foundation, Triage Cancer, and CancerCare, along with the manufacturer's own copay or patient-assistance program. They offer free, expert, cancer-focused support, and they can help you understand your options and protect your access to treatment. ---
- PAN Foundation Copay and financial assistance funds for specific diagnoses.
- Patient Advocate Foundation Case managers who help with insurance denials and appeals for serious illness.
- Triage Cancer Free education and resources on cancer-related insurance and appeals.
- CancerCare Professional support services and financial assistance.
Oncology clinics and manufacturers
Apellica partners with infusion centers, oncology practices, and pharmaceutical manufacturers on denial recovery and patient access at scale. If you are exploring a partnership, we would like to talk.
Partner with usFrequently asked questions
- Why do insurers deny Tecentriq?
- Prior authorization not documented; Biomarker or staging requirements; Site-of-care restrictions.
- Can I appeal a Tecentriq denial?
- Yes. You generally have the right to an internal appeal and then an independent external review under federal rules such as 45 CFR 147.136. For cancer-specific help, the organizations listed on this page specialize in oncology coverage.